Sarepta Therapeutics Stock Performance

SRPT Stock  USD 115.45  2.06  1.75%   
The entity has a beta of 0.51, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Sarepta Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Sarepta Therapeutics is expected to be smaller as well. At this point, Sarepta Therapeutics has a negative expected return of -0.0714%. Please make sure to validate Sarepta Therapeutics' treynor ratio and daily balance of power , to decide if Sarepta Therapeutics performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sarepta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Sarepta Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more

Actual Historical Performance (%)

One Day Return
(1.75)
Five Day Return
(2.94)
Year To Date Return
(6.96)
Ten Year Return
862.08
All Time Return
196.03
Last Split Factor
1:6
Last Split Date
2012-07-12
1
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
10/30/2024
2
Disposition of 1636 shares by Boor Kathryn Jean of Sarepta Therapeutics at 125.55 subject to Rule 16b-3
12/05/2024
3
Disposition of 10500 shares by Wigzell Hans Lennart Rudolf of Sarepta Therapeutics at 13.71 subject to Rule 16b-3
12/12/2024
4
Sarepta Therapeutics Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue
01/13/2025
5
JJ files a potential blockbuster Lykos shakes up its board
01/15/2025
Begin Period Cash Flow985.8 M
  

Sarepta Therapeutics Relative Risk vs. Return Landscape

If you would invest  12,329  in Sarepta Therapeutics on November 1, 2024 and sell it today you would lose (784.00) from holding Sarepta Therapeutics or give up 6.36% of portfolio value over 90 days. Sarepta Therapeutics is currently does not generate positive expected returns and assumes 2.8891% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Sarepta, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Sarepta Therapeutics is expected to under-perform the market. In addition to that, the company is 3.37 times more volatile than its market benchmark. It trades about -0.02 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.

Sarepta Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Sarepta Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sarepta Therapeutics, and traders can use it to determine the average amount a Sarepta Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0247

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsSRPT

Estimated Market Risk

 2.89
  actual daily
25
75% of assets are more volatile

Expected Return

 -0.07
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.02
  actual daily
0
Most of other assets perform better
Based on monthly moving average Sarepta Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sarepta Therapeutics by adding Sarepta Therapeutics to a well-diversified portfolio.

Sarepta Therapeutics Fundamentals Growth

Sarepta Stock prices reflect investors' perceptions of the future prospects and financial health of Sarepta Therapeutics, and Sarepta Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sarepta Stock performance.

About Sarepta Therapeutics Performance

Assessing Sarepta Therapeutics' fundamental ratios provides investors with valuable insights into Sarepta Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Sarepta Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 901.41  856.34 
Return On Tangible Assets(0.15)(0.16)
Return On Capital Employed(0.10)(0.12)
Return On Assets(0.15)(0.16)
Return On Equity(0.56)(0.59)

Things to note about Sarepta Therapeutics performance evaluation

Checking the ongoing alerts about Sarepta Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sarepta Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Sarepta Therapeutics generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 1.24 B. Net Loss for the year was (535.98 M) with profit before overhead, payroll, taxes, and interest of 609.29 M.
Sarepta Therapeutics currently holds about 2.07 B in cash with (500.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61.
Sarepta Therapeutics has a poor financial position based on the latest SEC disclosures
Over 92.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
Evaluating Sarepta Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Sarepta Therapeutics' stock performance include:
  • Analyzing Sarepta Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sarepta Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Sarepta Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Sarepta Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sarepta Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Sarepta Therapeutics' stock. These opinions can provide insight into Sarepta Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Sarepta Therapeutics' stock performance is not an exact science, and many factors can impact Sarepta Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.